Apremilast, a PDE4 inhibitor, works by reducing the production of pro-inflammatory cytokines, including TNF-α, IL-17 and IL-23, which are involved in various inflammatory skin diseases.10 Its efficacy in this case is noteworthy, as the patient achieved complete remission without significant adverse effects. Here, PDE4A is linked to inflammatory skin disease.